Neurocrine Biosciences (NBIX) Scheduled to Post Quarterly Earnings on Wednesday

Neurocrine Biosciences (NASDAQ:NBIX) is scheduled to post its quarterly earnings results before the market opens on Wednesday, May 1st. Analysts expect Neurocrine Biosciences to post earnings of $1.04 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The company had revenue of $515.20 million for the quarter, compared to the consensus estimate of $518.52 million. During the same period last year, the firm posted $0.88 EPS. The company’s revenue for the quarter was up 25.0% on a year-over-year basis. On average, analysts expect Neurocrine Biosciences to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Neurocrine Biosciences Stock Up 4.8 %

Shares of NASDAQ:NBIX opened at $140.09 on Wednesday. The firm has a 50-day simple moving average of $136.34 and a 200 day simple moving average of $127.54. Neurocrine Biosciences has a fifty-two week low of $89.04 and a fifty-two week high of $148.37. The company has a market cap of $13.94 billion, a PE ratio of 57.89 and a beta of 0.25.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on NBIX. Wedbush reiterated an “outperform” rating and set a $147.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday, April 17th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, April 10th. StockNews.com raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Citigroup dropped their price objective on shares of Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating on the stock in a report on Thursday, February 8th. Finally, Wells Fargo & Company boosted their target price on shares of Neurocrine Biosciences from $127.00 to $140.00 and gave the company an “equal weight” rating in a research note on Thursday, February 8th. Seven equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $139.67.

Insider Activity

In other news, insider Ingrid Delaet sold 200 shares of the business’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $140.00, for a total transaction of $28,000.00. Following the sale, the insider now directly owns 7,507 shares of the company’s stock, valued at $1,050,980. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Ingrid Delaet sold 200 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $140.00, for a total value of $28,000.00. Following the completion of the sale, the insider now owns 7,507 shares in the company, valued at approximately $1,050,980. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Eric Benevich sold 19,818 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the completion of the transaction, the insider now directly owns 40,778 shares of the company’s stock, valued at approximately $5,438,154.08. The disclosure for this sale can be found here. In the last 90 days, insiders sold 186,994 shares of company stock worth $25,806,409. Insiders own 4.40% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.